In vitro cytotoxicity, cellular uptake, reactive oxygen species and cell cycle arrest studies of novel ruthenium(II) polypyridyl complexes towards A549 lung cancer cell line

References

• Arany, I., and Safirstein, R.L., 2003. Cisplatin nephrotoxicity. Seminars in Nephrology, 23 (5), 460–464. Available at: http://www.ncbi.nlm.nih.gov/pubmed/13680535 (Accessed: 15 December 2017).
   PubMed Web of Science ®Google Scholar
• Bergamo, A., et al., 1999. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. The Journal of Pharmacology and Experimental Therapeutics, 289 (1), 559–564. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10087050.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., 2016. Two-photon luminescent metal complexes for bioimaging and cancer phototherapy. Coordination Chemistry Reviews. Elsevier B.V, 310, 16–40.
   Web of Science ®Google Scholar
• Chen, T., et al., 2010. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. 49 (14), 6366–6368.
   Google Scholar
• Chen, Z.F., et al., 2015. Water-soluble ruthenium(II) complexes with chiral 4-(2,3-dihydroxypropyl)-formamide oxoaporphine (FOA): In vitro and in vivo anticancer activity by stabilization of G-quadruplex DNA, inhibition of telomerase activity, and induction of tumor cell apoptosis. Journal of Medicinal Chemistry, 58 (11), 4771–4789.
   PubMed Web of Science ®Google Scholar
• Deng, Z., et al., 2017. Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells. Biomaterials, 129, 111–126.
   PubMed Web of Science ®Google Scholar
• Dolmans, D.E.J.G.J., Fukumura, D., and Jain, R.K., 2003. TIMELINE: photodynamic therapy for cancer. Nature Reviews Cancer, 3 (5), 380–387.
   PubMed Web of Science ®Google Scholar
• Frei, A., et al., 2014. Synthesis, characterization, and biological evaluation of new RU(ii) polypyridyl photosensitizers for photodynamic therapy supporting information. Journal of Medicinal Chemistry, 57 (17), 7280–7292.
   PubMed Web of Science ®Google Scholar
• Gill, M.R., et al., 2011. Ruthenium (II) metallo-intercalators : DNA imaging and cytotoxicity. European Journal of Chemical Biology, 12 (6), 877–880.
   Google Scholar
• Gill, M.R., and Thomas, J.A., 2012. Ruthenium(ii) polypyridyl complexes and DNA—from structural probes to cellular imaging and therapeutics. Chemical Society Reviews, 41 (8), 3179.
   PubMed Web of Science ®Google Scholar
• Gonzalez, R.J., and Tarloff, J.B., 2001. Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity. Toxicology in Vitro : An International Journal Published in Association with BIBRA, 15 (3), 257–259. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11377098 (Accessed: 30 November 2017).
   PubMed Web of Science ®Google Scholar
• Graf, N., et al., 2012. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug . ACS Nano, 6 (5), 4530–4539.
   PubMed Web of Science ®Google Scholar
• Guo, Q.-F., et al., 2012. Synthesis, characterization, photocleavage, cytotoxicity in vitro, apoptosis, and cell cycle arrest of ruthenium(II) complexes. Journal of Coordination Chemistry, 65 (10), 1781–1791.
   Web of Science ®Google Scholar
• Han, B.-J., et al., 2014. The studies on bioactivity in vitro of ruthenium (ii) polypyridyl complexes towards human lung carcinoma A549 cells’, RSC Advances. The Royal Society of Chemistry, 4 (77), 40899–40906.
   Web of Science ®Google Scholar
• Huang, H.-L., et al., 2010. Studies of ruthenium(II) polypyridyl complexes on cytotoxicity in vitro, apoptosis, DNA-binding and antioxidant activity. Journal of Molecular Structure, 966 (1–3), 136–143. Elsevier,
   Web of Science ®Google Scholar
• Hummer, A.A., et al., 2013. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans -[tetrachlorobis(1 H -indazole)ruthenate(III)] (KP1019). Journal of Medicinal Chemistry, 56 (3), 1182–1196.
   PubMed Web of Science ®Google Scholar
• Jiang, G.-B., et al., 2013. Synthesis, characterization, DNA interaction, antioxidant and anticancer activity studies of ruthenium(II) polypyridyl complexes. Journal of Photochemistry and Photobiology. B, Biology. Elsevier B.V, 129, 48–56.
   PubMed Web of Science ®Google Scholar
• Jiang, G.-B., et al., 2014. The induction of apoptosis in BEL-7402 cells through the ROS-mediated mitochondrial pathway by a ruthenium(ii) polypyridyl complex. New Journal of Chemistry, 38 (6), 2554–2563.
   Web of Science ®Google Scholar
• Kessel, D., and Luo, Y., 2000. Cells in cryptophycin-induced cell-cycle arrest are susceptible to apoptosis. Cancer Letters, 151 (1), 25–29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10766419 (Accessed: 12 December 2017).
   PubMed Web of Science ®Google Scholar
• Lai, S.H., et al., 2015. Cytotoxic activity, DNA damage, cellular uptake, apoptosis and western blot analysis of ruthenium(II) polypyridyl complex against human lung decarcinoma A549 cell. Journal of Inorganic Biochemistry, B.V, 152 (Ii), 1–9.
   PubMedGoogle Scholar
• Lai, S.-H., et al., 2016. Apoptosis, autophagy, cell cycle arrest, cell invasion and BSA-binding studies in vitro of ruthenium (ii) polypyridyl complexes. RSC Advances, 6 (68), 63143–63155.
   Web of Science ®Google Scholar
• Li, W., et al., 2014a. Synthesis, characterization and cytotoxic activity studies of two ruthenium (II) complexes. Inorganica Chimica Acta. Elsevier B.V, 423, 229–234.
   Web of Science ®Google Scholar
• Li, W., et al., 2014b. Ruthenium(II) complexes: DNA-binding, cytotoxicity, apoptosis, cellular localization, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential and western blot analysis. Journal of Photochemistry and Photobiology B: Biology. Elsevier B.V, 140, 94–104.
   PubMed Web of Science ®Google Scholar
• Liang, R., et al., 2014. Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics. Chemical Communications (Cambridge, England)), 50 (91), 14071–14081.
   PubMed Web of Science ®Google Scholar
• Lin, B., et al., 2014. A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. Scientific Reports, 4, 7041.
   PubMed Web of Science ®Google Scholar
• Liu, S.-H., et al., (2016). Protein-binding, cytotoxicity in vitro and cell cycle arrest of ruthenium(II) polypyridyl complexes. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 161, 77–82.
   PubMedGoogle Scholar
• Liu, Y.-J., et al., 2011a. Ruthenium(II) polypyridyl complexes: synthesis and studies of DNA binding, photocleavage, cytotoxicity, apoptosis, cellular uptake, and antioxidant activity. DNA and Cell Biology, 30 (10), 829–838.
   PubMed Web of Science ®Google Scholar
• Liu, Y.-J., et al., 2011b. Cytotoxicity, apoptosis, cellular uptake, cell cycle arrest, photocleavage, and antioxidant activity of 1, 10-phenanthroline ruthenium(II) complexes. DNA and Cell Biology, 30 (10), 839–848.
   PubMed Web of Science ®Google Scholar
• Mari, C., et al., 2015. Combination of Ru(ii) complexes and light: new frontiers in cancer therapy. Chemical Science, 6 (5), 2660–2686.
   PubMed Web of Science ®Google Scholar
• O’Neill, L., Perdisatt, L., and O’Connor, C., 2018. Structure-property relationships for a series of ruthenium (II) polypyridyl complexes elucidated through Raman spectroscopy. Journal of Spectroscopy, 2018, 3827130.
   Web of Science ®Google Scholar
• O’Neill, L., Perdisatt, L., and O’Connor, C., 2012. Influence of auxiliary ligands on the photophysical characteristics of a series of ruthenium(II)-polypyridyl complexes. The Journal of Physical Chemistry A, 116 (44), 10728–10735.
   PubMed Web of Science ®Google Scholar
• Page, S., 2012. Ruthenium compounds as anticancer agents. Education in Chemistry, 13 (9), 26–29.
   Google Scholar
• Page, B., Page, M., and Noel, C., 1993. A new fluorometric assay for cytotoxicity measurements in-vitro. International Journal of Oncology, 3 (3), 473–476. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21573387 (Accessed: 30 November 2017).
   PubMed Web of Science ®Google Scholar
• Perdisatt, L., et al., 2018. Synthesis, characterisation and DNA intercalation studies of regioisomers of ruthenium (II) polypyridyl complexes. Journal of Inorganic Biochemistry, 182, 71–82.
   PubMed Web of Science ®Google Scholar
• Puckett, C.A., and Barton, J.K., 2007. Methods to explore cellular uptake of ruthenium complexes. Journal of the American Chemical Society, 129 (1), 46–47.
   PubMed Web of Science ®Google Scholar
• Puckett, C.A., and Barton, J.K., 2009. Mechanism of cellular uptake of a ruthenium polypyridyl complex. Biochemistry, 47 (45), 11711–11716.
   Web of Science ®Google Scholar
• Purohit, A., et al., 2000. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. International Journal of Cancer, 85 (4), 584–589.
   PubMed Web of Science ®Google Scholar
• Rampersad, S.N., 2012. Multiple applications of Alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel, Switzerland). Multidisciplinary Digital Publishing Institute (MDPI), 12 (9), 12347–12360.
   PubMed Web of Science ®Google Scholar
• Schumacker, P.T., 2006. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell, 10 (3), 175–176.
   PubMed Web of Science ®Google Scholar
• Sledge, G.W., et al., 1988. Cisplatin as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 6 (12), 1811–1814.
   PubMed Web of Science ®Google Scholar
• Sun, J., et al., 2015. Synthesis, characterization, DNA interaction, and in vitro cytotoxicity activities of two ruthenium(II) complexes with disubstituted 2,2′-dipyridyl ligands bearing ammonium groups. Journal of Coordination Chemistry. 68 (2), 308–320.
   Web of Science ®Google Scholar
• Wan, D., et al., 2017. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption. European Journal of Medicinal Chemistry, 139, 180–190.
   PubMed Web of Science ®Google Scholar
• Wang, J., and Yi, J., 2008. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biology & Therapy, 7 (12), 1875–1884.
   PubMed Web of Science ®Google Scholar
• Zeng, L., et al., 2017. The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews, 46 (19), 5771–5804.
   PubMed Web of Science ®Google Scholar